These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 18369536

  • 1. The pharmacodynamic properties of azithromycin in a kinetics-of-kill model and implications for bacterial conjunctivitis treatment.
    Dorfman MS, Wagner RS, Jamison T, Bell B, Stroman DW.
    Adv Ther; 2008 Mar; 25(3):208-17. PubMed ID: 18369536
    [Abstract] [Full Text] [Related]

  • 2. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.
    Hansen CR, Pressler T, Hoiby N, Johansen HK.
    J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
    Zhanel GG, DeCorby M, Noreddin A, Mendoza C, Cumming A, Nichol K, Wierzbowski A, Hoban DJ.
    J Antimicrob Chemother; 2003 Jul; 52(1):83-8. PubMed ID: 12775677
    [Abstract] [Full Text] [Related]

  • 4. Microbiologic effect of bovine cerebrospinal fluid and azithromycin against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae.
    Destache CJ, Pakiz CB, Kersting K.
    Pharmacotherapy; 1997 Jul; 17(5):985-9. PubMed ID: 9324186
    [Abstract] [Full Text] [Related]

  • 5. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.
    D'Arienzo PA, Wagner RS, Jamison T, Bell B, Dajcs JJ, Stroman DW.
    Adv Ther; 2010 Jan; 27(1):39-47. PubMed ID: 20174904
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains.
    Treyaprasert W, Schmidt S, Rand KH, Suvanakoot U, Derendorf H.
    Int J Antimicrob Agents; 2007 Mar; 29(3):263-70. PubMed ID: 17194570
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of 50S ribosomal subunit assembly in Haemophilus influenzae cells by azithromycin and erythromycin.
    Champney WS, Miller M.
    Curr Microbiol; 2002 Jun; 44(6):418-24. PubMed ID: 12000992
    [Abstract] [Full Text] [Related]

  • 8. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates.
    Asbell PA, Colby KA, Deng S, McDonnell P, Meisler DM, Raizman MB, Sheppard JD, Sahm DF.
    Am J Ophthalmol; 2008 Jun; 145(6):951-958. PubMed ID: 18374299
    [Abstract] [Full Text] [Related]

  • 9. A time-kill evaluation of clarithromycin and azithromycin against two extracellular pathogens and the development of resistance.
    Burgess DS, Hastings RW, Horan JL.
    Ann Pharmacother; 1999 Dec; 33(12):1262-5. PubMed ID: 10630825
    [Abstract] [Full Text] [Related]

  • 10. Speed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: clinical implications and a review of kinetics of kill studies.
    Lichtenstein SJ, Wagner RS, Jamison T, Bell B, Stroman DW.
    Adv Ther; 2007 Dec; 24(5):1098-111. PubMed ID: 18029337
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and antibacterial activity of novel 11,12-cyclic carbonate azithromycin 4''-O-carbamate derivatives.
    Ma C, Liu Z, Song H, Jiang R, He F, Ma S.
    J Antibiot (Tokyo); 2010 Jan; 63(1):3-8. PubMed ID: 19911029
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of the ketolide ABT-773.
    Barry AL, Fuchs PC, Brown SD.
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2922-4. PubMed ID: 11557491
    [Abstract] [Full Text] [Related]

  • 13. Azithromycin iv pharmacodynamic parameters predicting Streptococcus pneumoniae killing in epithelial lining fluid versus serum: an in vitro pharmacodynamic simulation.
    Sevillano D, Alou L, Aguilar L, Echevarría O, Giménez MJ, Prieto J.
    J Antimicrob Chemother; 2006 Jun; 57(6):1128-33. PubMed ID: 16617063
    [Abstract] [Full Text] [Related]

  • 14. Microbiological features of acute bacterial conjunctivitis in a central Italian area.
    Montagnani F, Malandrini A, Stolzuoli L, Lomurno L, Buccoliero D, Zanchi A.
    New Microbiol; 2008 Apr; 31(2):291-4. PubMed ID: 18623997
    [Abstract] [Full Text] [Related]

  • 15. Topical ophthalmic moxifloxacin elicits minimal or no selection of fluoroquinolone resistance among bacteria isolated from the skin, nose, and throat.
    Lichtenstein SJ, De Leon L, Heller W, Marshall B, Cupp G, Foster K, McLean C, Levy S, Stroman DW.
    J Pediatr Ophthalmol Strabismus; 2012 Apr; 49(2):88-97. PubMed ID: 22074357
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis.
    Ohnsman C, Ritterband D, O'Brien T, Girgis D, Kabat A.
    Curr Med Res Opin; 2007 Sep; 23(9):2241-9. PubMed ID: 17688706
    [Abstract] [Full Text] [Related]

  • 20. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
    Berry V, Thorburn CE, Knott SJ, Woodnutt G.
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3193-9. PubMed ID: 9835514
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.